Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVMXY's Cash-to-Debt is ranked higher than
94% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVMXY' s Cash-to-Debt Range Over the Past 10 Years
Min: 7  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.80
AVMXY's Equity-to-Asset is ranked higher than
77% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. AVMXY: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
AVMXY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.84 Max: 0.96
Current: 0.8
0.51
0.96
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked higher than
94% of the 225 Companies
in the Global Medical Devices industry.

( Industry Median: 77.23 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -5.19
WACC vs ROIC
3.48%
-784.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1376.05
AVMXY's Operating Margin % is ranked lower than
95% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. AVMXY: -1376.05 )
Ranked among companies with meaningful Operating Margin % only.
AVMXY' s Operating Margin % Range Over the Past 10 Years
Min: -1723.37  Med: -288.3 Max: -178.34
Current: -1376.05
-1723.37
-178.34
Net Margin % -776.25
AVMXY's Net Margin % is ranked lower than
91% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. AVMXY: -776.25 )
Ranked among companies with meaningful Net Margin % only.
AVMXY' s Net Margin % Range Over the Past 10 Years
Min: -1614.68  Med: -242.44 Max: -57.58
Current: -776.25
-1614.68
-57.58
ROE % -140.52
AVMXY's ROE % is ranked lower than
92% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. AVMXY: -140.52 )
Ranked among companies with meaningful ROE % only.
AVMXY' s ROE % Range Over the Past 10 Years
Min: -145.87  Med: -87.94 Max: -17.34
Current: -140.52
-145.87
-17.34
ROA % -110.75
AVMXY's ROA % is ranked lower than
90% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.13 vs. AVMXY: -110.75 )
Ranked among companies with meaningful ROA % only.
AVMXY' s ROA % Range Over the Past 10 Years
Min: -111.43  Med: -65.83 Max: -13.45
Current: -110.75
-111.43
-13.45
ROC (Joel Greenblatt) % -700.34
AVMXY's ROC (Joel Greenblatt) % is ranked lower than
83% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. AVMXY: -700.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVMXY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4361.27  Med: -834.71 Max: -248.87
Current: -700.34
-4361.27
-248.87
3-Year Revenue Growth Rate -39.40
AVMXY's 3-Year Revenue Growth Rate is ranked lower than
92% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. AVMXY: -39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVMXY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -39.4 Max: 8.7
Current: -39.4
0
8.7
3-Year EBITDA Growth Rate -5.20
AVMXY's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. AVMXY: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVMXY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.1  Med: -11.3 Max: 30.8
Current: -5.2
-64.1
30.8
3-Year EPS without NRI Growth Rate -8.00
AVMXY's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. AVMXY: -8.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVMXY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.9  Med: -16 Max: 11.9
Current: -8
-57.9
11.9
GuruFocus has detected 5 Warning Signs with Avita Medical Ltd $AVMXY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVMXY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:OTCPK:BLOZF, OTCPK:BTCY, NAS:RWLK, OTCPK:IVOB, AMEX:ELMD, NAS:TNDM, OTCPK:GIDYL, NAS:MGCD, NAS:ETRM, OTCPK:FGCN, OTCPK:TLTFF, OTCPK:BSGM, NAS:KOOL, NAS:SRTS, OTCPK:VICA, OTCPK:QTVLF, NAS:PAVM, OTCPK:DIZTF, OTCPK:ZMSPF, OTCPK:LCTC » details
Traded in other countries:AVH.Australia, GCR.Germany,
Headquarter Location:UK
Avita Medical Ltd develops and distributes autologous regenerative products. The Company's product portfolio includes ReCell for burns procedures, ReGenerCell for chronic wounds and ReNovaCell of restoration of pigmentation and cosmesis.

Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.

Top Ranked Articles about Avita Medical Ltd

Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell® in a Mass Casualty Scenario
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 19, 2016) - Avita Medical Ltd, (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, has identified distribution partners for its medical devices in South Africa and the three Benelux nations, the Company said today. Avita said the appointments followed detailed due diligence of both new distributors, which included favourable evaluations of the considerable potential of these differing markets. The Company is gradually expanding its international footprint, with 17 countries now covered under its distributor network, whose members must show demonstrable reach into the woundcare sector and the ability to sell breakthrough medical devices. In South Africa, Baroque Medical, an importer and distributor of surgical and medical devices, will initially focus on the country's sizable burns sector. South Africa's health care system annually treats approximately 1.5 million burns patients, making it one of the world's largest per capita burns populations. Within this group, some 230,000 are rated as moderate to severe, and would be regarded by Avita as appropriate for ReCell® treatment. Baroque Medical has already introduced ReCell® to major public and private hospital burns units, such as the Burns Unit of Chris Hani Baragwanath Hospital, Johannesburg, the Red Cross War Memorial Children's Hospital, Western Cape, and the Nelspruit Mediclinic in Mpumalanga. As part of Baroque's clinical evaluation, doctors have used ReCell® to treat large burns on six patients, all of whom are reported to be healing well. Baroque Medical recently unveiled ReCell® at a national meeting of the Association of Plastic and Reconstructive Surgeons of Southern Africa. "ReCell® is a hugely innovative product, and we are very excited about how surgeons can deploy it, especially for larger body surface area burns that require hospitalisation," said Jason Thompson National Sales Manager - Advanced Wound Care of Baroque Medical. "We have a very high prevalence of burn injuries in South Africa, and there are many acute cases that would benefit from this life-changing technology." Avita has also agreed to commercial terms with LD Medical, a Belgium-based medical devices company that has experience in burns and trauma response in its distribution across Belgium, Holland and Luxemburg. LD Medical will initially focus on three major Burns centers in the Netherlands and four in Belgium, including the Military Burns Center Reine Elisabeth in Brussels. Belgium burns centers treat approximately 1,000 patients a year. Clinical evaluations of ReCell® have commenced, and LD Medical CEO Luc De Myttenaere said initial feedback from surgeons and patients had been very positive. "South Africa and the Benelux countries, whilst different in their prospects, both represent particular opportunities to bring the benefits of our ReCell® devices to patients," said Avita Medical's CEO, Adam Kelliher. "We are confident that we have found the right partners in these territories, and that they will be able to explain to medical professionals the verities of our breakthrough approach to wound healing." Avita Medical provides clinical support to its distributors sales teams, to help in their interactions with medical professionals. Over the past year, Avita has escalated its commercialization activities with new distributors appointed in the UK, Germany, France, China, Japan, South Korea, Malaysia and Iran. ABOUT AVITA MEDICAL LIMITED Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's regenerative product portfolio includes ReCell® for burns & plastic reconstructive procedures, ReGenerCell® for chronic wounds and ReNovaCell® of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell® and ReNovaCell® are patented, CE‐marked for Europe. ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com. AVITA'S REGENERATIVE TECHNOLOGY AND RES™ Avita Medical's unique proprietary technology enables a clinician to rapidly create, at the point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell(R) in Life-Threatening Injuries

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 18, 2016) -

Up to 48 patients can now be treated at 15 US burns centers Increased use of ReCell® device by US surgeons under the Compassionate Use dispensations Latest FDA approval separate to approval earlier in the month for Continued Access





The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under special compassionate use protocols, Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) said today. The regenerative medicine company, which specializes in the treatment of wounds and skin defects, said the FDA had given a third expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®, allowing the company to treat up to 48 patients who have insufficient healthy skin available for standard skin grafting of their injury. The FDA also increased to 15 the number of hospitals that could deploy the protocol. Several of these hospitals have been introduced to Avita's autologous cell harvesting approach under the Company's FDA approval trial, which is on schedule and now in a safety and observation period following treatment of all enrolled patients. "We welcome this compassionate use expansion, which will allow surgeons to further deploy our devices in the U.S. for patients who suffer extensive injuries, and are in a life-threatening condition," said Avita CEO Adam Kelliher. "It underlines our key proposition, that ReCell is a safe, powerful and effective means of facilitating healing. Most of the cases to date have been in burns, indicating the growing interest we are seeing within the U.S. burns community for our unique approach." Under the compassionate use protocol, use of ReCell® may be granted in cases where the patient's treating physician believes that there is no suitable alternative treatment. The FDA first approved the initial IDE for up to 12 subjects in life-threatening circumstances in April 2014. Applications have increased from surgeons to access the exemption, and in October 2015, the FDA doubled the number of patients permitted under the IDE, from 12 to 24 patients. In July this year, the number was again increased to 36 patients. To date, 34 compassionate use cases using ReCell® have been conducted at several leading institutions, including Wake Forest Baptist Medical Center, the Arizona Burn Center at Maricopa Medical Center, Walter Reed National Military Medical Center, MedStar Washington Hospital Center, University of California San Diego Health System, Regional Medical Center / University of Tennessee, the U.S. Army Institute for Surgical Research (San Antonio), University of South Alabama, Baton Rouge General Hospital and Riley Hospital for Children (Indianapolis). "We are grateful to the FDA for the opportunity to serve this highly vulnerable population," said Andrew Quick, Avita's Senior VP Clinical Development. "It also provides further opportunities to collaborate with leading U.S. surgeons to develop our understanding around what we anticipate will become best practice for treatment of skin injuries and defects in patients who have insufficient donor skin for conventional treatment." The expansion of the IDE follows the FDA's separate Oct. 5 approval of Continued Access, under which surgeons who are participating in the approval trial are also able to access ReCell®. Under that approval, up to 60 new patients could be treated under an exemption that allows doctors to access a medical device while the marketing application is under preparation and review, if 'there is a public need for the device,' and 'there is preliminary evidence that the device is likely to be effective and no significant safety concern have been identified for the proposed indication.' Avita is seeking a Pre Market Approval (PMA) for its ReCell® device, and its fully enrolled clinical trial has involved seven leading US burns centers. The Company says the programme is on track and it expects to submit its clinical data package in early 2017, with an anticipated market approval later in the year. ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


Australia

Monsoon Communications

Dean Felton

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 13, 2016) - Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, announced today that Timothy Rooney, Avita's Chief Financial Officer will provide a company overview at the Dawson James Securities Growth Stock Conference on October 20, 2016. The presentation will take place at 9:00 a.m. ET at the Wyndham Grand Hotel in Jupiter, Florida. The Second Annual Dawson James Growth Stock Conference features small cap growth companies within the Healthcare, Technology and Consumer sectors. Over 30 senior management teams will be presenting to a select invite-only audience including Institutional Funds, Family Offices and High Net Worth Accredited investors. Mr. Rooney's presentation will update audiences on Avita's commercial, regulatory, scientific and clinical research developments, providing recent data and outcomes across the range of indications for which the Company's portfolio of products (ReCell®, ReGenerCell™ and ReNovaCell™) are in use around the world. Mr. Rooney will also discuss Avita's contract award from the Biomedical Advanced Research and Development Authority (BARDA) for use of ReCell® as a medical countermeasure for US mass casualty preparedness. A review of the FDA approval pathway and progress will also be provided. Presentation details:

Date:  Thursday, 20 October

Time: 9:00 a.m. Eastern Time

Location: Preserve Ballroom B, Track 2, at the Wyndham Grand Hotel in Jupiter, FL, USA. ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com. About Dawson James Securities

Dawson James Securities, Inc., a member of FINRA/SIPC, is a full service investment bank headquartered in Boca Raton, FL. www.dawsonjames.com


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



Australia

Monsoon Communications

Dean Felton

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
FDA Approves Continued Access to ReCell(R) in US Burns Trial

Up to 60 US Burns Patients Could Be Treated Under the New Ruling

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 4, 2016) - The US Food and Drug Administration has approved Continued Access to ReCell, allowing US burns surgeons participating in Avita Medical's regulatory trial to treat new patients using the Company's cell harvesting device, while the marketing application is under preparation and review, the Company said today. Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, said up to 60 new patients could be treated under the the FDA's approval of an application for 'Continued Access to Investigational Devices.' The Continued Access provision of the FDA's Investigational Device Exemption (IDE) guidance allows doctors to access a medical device while the marketing application is under preparation and review, if 'there is a public need for the device,' and 'there is preliminary evidence that the device is likely to be effective and no significant safety concern have been identified for the proposed indication.' The FDA's principles on granting the Continued Access further state that 'it could be contrary to public health to prevent access to potentially safe and effective new devices during an evaluation period.' Avita has already treated all the 30 patients required for its approval trial, being conducted at seven leading burns centres across the US, and this group are now within a safety observation period. Once that phase has been completed in early 2017, the Company will submit an application for Pre Market Approval (PMA), and hopes its ReCell® device will get approval before the end of 2017. In tandem to the approval process, the Company also has FDA approval of an IDE for Compassionate Use, under which burns patients can be treated with ReCell® -- an autograft sparing device -- if their life is in danger and there is no other treatment alternative. More than 30 American burns and trauma victims, most with very large-scale injuries, have been treated to date under this protocol. Now, under Continued Access, the surgeons who participated in the trial will be able to access ReCell®, for their patients who require grafting, but whose injuries do not meet the criteria for Compassionate Use. Further, the surgeons will record the treatment in compliance with the approval trial protocols, which will contribute to the body of clinical data being amassed around Avita's regenerative medical approach. "It is heartening that more US burns patients will now be able to receive our unique treatment approach during the pre-approval period," said Andy Quick, Senior VP of Clinical Development. "But it is also important that those surgeons who had adopted ReCell® into their practice will now be able to again deploy the device and further see its effectiveness, beyond what they have seen to date." Adam Kelliher, Avita CEO, said the approval was a positive step within the context of Avita's plans to enter the US healthcare market, the world's largest. "It is a very positive step that the FDA have decided that we comply with the guiding criteria for Continued Access, under which eligible devices must be assessed as safe, effective and meeting a real public need," Kelliher said. "At the same time my team remains on track to meet our stated objectives and achieve US market approval." ABOUT AVITA MEDICAL LIMITED Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's regenerative product portfolio includes ReCell® for burns & plastic reconstructive procedures, ReGenerCell® for chronic wounds and ReNovaCell® of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell® and ReNovaCell® are patented, CE‐marked for Europe. ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval. To learn more, visit www.avitamedical.com. AVITA'S REGENERATIVE TECHNOLOGY AND RES™ Avita Medical's unique proprietary technology enables a clinician to rapidly create, at the point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


Australia

Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: 61 3 9620 3333

[email protected]





Read more...
Avita Medical Signs Exclusive Distributor Deal in Iran

Dedicated ReNovaCell(TM) Clinic to Open in Tehran

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Sep 28, 2016) - A dedicated clinic for Avita Medical's regenerative medical devices will soon open in Iran following the appointment of an exclusive distributor in this significant aesthetic market, the Company (ASX: AVH) (OTCQX: AVMXY), said today. Avita Medical Ltd, a regenerative medicine company specialising in new treatments for wounds and skin defects, said the clinic in Tehran would in the first instance treat patients for repigmentation and scar reconstruction. The planned clinic is part of a distribution deal with Teb Sanaat Lotus, an Iranian-based company, which will distribute Avita's products through Zikad International Aesthetics Supplier, its Iranian partner company. Zikad is an established brand in Iran, through four high-end aesthetics clinics as well as supplying premium aesthetic products across the country by its 28 dedicated sales staff. Besides procedures, Zikad's ReNovaCell™ Clinic will also act as a training center, partnering with other private clinics, and enabling clinicians to offer the treatment countrywide. Zikad also plans to expand into the burns and chronic wound markets in coming months. Approximately 16 million people undergo aesthetic procedures in Iran every year, making it the tenth biggest market in the world, and the second largest in the Middle East. There are some 1,400 clinics and 2,600 doctors working in Iran's aesthetic arena, and Avita said the sector appeared poised for significant growth now that international sanctions have been lifted. "Using a dedicated clinic is a new approach for Avita, and we believe it will give us real focus to reach this important market," said Avita Medical's CEO, Adam Kelliher. "The dedicated ReNovaCell™ clinic and training center should support the rapid adoption of our skin renewal technology. And when this platform is further rolled out to burns and chronic wounds, we anticipate Iran will become a significant market for Avita."  The Company said there were obvious applications for its ReCell™ device, as burns leave some 150,000 sufferers hospitalised a year in Iran, a level some eight times higher than the average global rate. Further, the country is an obvious strong market for Avita's ReGenerCell ™ device, as Iran has an estimated 800,000 chronic wounds patients, leading to some 175,000 amputations performed annually. "Using our strong distribution network and distinguished medical contacts, we are confident that we can create a strong demand for Avita's ReNovaCell™ and its other regenerative skin healing products in Iran," said Aram Mousavi of Zikad International Aesthetics Supplier. "There is real excitement about this unique approach and how we can deploy it to give better outcomes in these sizable patient groups." Avita Medical will provide clinical support to the Zikad's sales team and extended agent network, to help in their interactions with medical professionals. The distribution agreement is a significant step for Avita's growth strategy in the Middle East. Over the past year, Avita has announced the escalation of its commercialization activities with distributors appointed in the UK, Germany, Austria, France, Switzerland, China, Japan and South Korea. ABOUT AVITA MEDICAL LIMITED Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com. AVITA'S REGENERATIVE TECHNOLOGY AND RES™ Avita Medical's unique proprietary technology enables a clinician to rapidly create, at the point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.


FOR FURTHER INFORMATION



Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0)894747738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



Australia

Monsoon Communications

Dean Felton

Phone: 61 3 9620 3333

Mobile: 61(0)411698499

[email protected]





Read more...
Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Sep 22, 2016) - Avita Medical Ltd (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today it will host a ReCell® Symposium at the EBA Educational Course, taking place in Birmingham, UK, 26-27 September. The Symposium 'Experiences of ReCell® in burns treatment and scar revision' will support the education and adoption of new technologies and share the experiences of lead clinicians who have used ReCell® for burns. The Symposium is taking place at 9.10 a.m. during Session 4: Post burn reconstruction C. Speakers taking part in the Symposium are: Ms Isabel Jones - Plastic Surgeon, Chelsea and Westminster Hospital London

Professor Matthias Aust - Plastic and Aesthetic Surgeon, Malteser Hospital, Bonn

Dr Shehzadi Kohli - Plastic, Reconstructive, Hand, Aesthetic and Burn Surgeon - Klinikum Bogenhausen, Munich

Dr Simon Kuepper - Plastic and Aesthetic Surgeon, Unfallkrankenhaus, Berlin

Dr Christopher Dunnill - University of Huddersfield The EBA Educational Course is a bi-annual event which sees 300 delegates, including plastic surgeons, anesthesiologists, nurse specialists and burn team members from Europe and beyond. This year's theme is Burns at the Extremes of Age, incorporating acute care and resuscitation, infection and sepsis, skin substitutes; present and future and psychological aspects of burns. To meet the Avita team, visit Stand 8 in the exhibition hall. ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com. About ReCell®

ReCell® is a medical device which enables clinicians to safely and rapidly create a treatment solution for burns and acute injuries from a patient's own skin. Using a small sample of skin, the device enables the production of a Regenerative Epithelial Suspension (RES™). The autologous suspension contains the multi-phenotype cells and wound-healing factors essential for natural healthy skin regeneration and healing. The procedure performed at the patient's bedside takes about 30 minutes from collecting the biopsy to spraying of the suspension onto the affected area. ReCell® can be used in conjunction with conventional treatments for burns and reconstructive procedures, and has been used safely in thousands of treatments worldwide. Recent data showed that treatment of ReCell® decreased length of hospital stay in patients with large burns by 47%. For more information, visit: http://avitamedical.com/clinicians/burns-clinician/how-it-works


FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]



Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]



UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]



Australia

Monsoon Communications

Dean Felton

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical Appoints a Leading Health Economics Group

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 28, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY) has engaged a leading Health Economics Group to evaluate how its novel regenerative medical device, ReCell®, can save money at US burns centres, the Company said today. The regenerative medicine company, which specializes in new treatments for wounds and skin defects, said the commissioned study would be funded by BARDA, the US federal authority which prepares the US for possible mass casualty events, and with which Avita has a US$61.9m (A$84.2m) development and procurement contract. IMS Health, one of the world's leading health economic groups, had been selected for the project, which should take six to eight months, and has a broad remit to explore the potential cost savings from all major interventions for burns treatment, including wound bed preparation, grafting and scar management. In its proposal to Avita, IMS reported that burns place an economic burden on the US medical system of more than $1.5bn pa, half of this spent on the some 40,000 patients who are hospitalised with severe burns. The agency said that these costs could increases significantly if there was armed conflict or a mass casualty event, given that up to 10% of combat injuries are burns, and that burns typically increase three-fold amongst civilians during wartime. "Burns remain the fourth most common trauma in the international community, and cause 1% of non-fatal injuries in the US" IMS reported. "Although burn fatalities have fallen over time, effectively managing burns remains a challenge, with significant morbidity and mortality among burn patients. Potential effects include shock, infection, electrolyte imbalance, respiratory distress, incapacitation, disfigurement, pain, and psychological complications due to scarring and deformity." In a review of potential economic benefits, IMS summarised that ReCell®'s technology achieved faster epithelialisation of widely-meshed skin graft interstices and thus minimized donor site requirements. It also showed improved long-term functional and aesthetic outcomes of grafting while also minimizing follow-on procedure requirements, the IMS report said. "We have data to show that ReCell® is safe, and very effective in treating burns," said Avita CEO Adam Kelliher. "What we must also demonstrate is how our approach, in conjunction with other treatments, can save public health bodies money, by getting patients out of hospital faster, and improving their outcomes. The IMS study will generate standard budget impact metrics vital to driving discussions on reimbursement and access." ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke, Investor Relations

Kirsten Thomas, Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected]

/ [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 27, 2016) - Avita Medical's autologous skin healing technology shows strong effectiveness in treating burns, chronic wounds and aesthetics, and will help strained public health budgets, according to a comprehensive review of data presented at a scientific symposium by a leading Regenerative Medicine journal, the Company said today. Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, ran the 4th Skin Regeneration Symposium (SRS) in Cambridge, UK in April 2016. Data from the event, presented by leading clinicians worldwide to the some 140 attendees, has now been published on RegMedNet.com, which is the online platform for peer-reviewed journal Regenerative Medicine. The full three-part review together with clinician interviews are published with free access at Regenerative Medicine.

Part 1 covers the REPAIR session of the Symposium, focused on ReCell®, Avita's proprietary technology for the treatment of burns
Part 2, on the RESTART session which concentrated on ReGenerCell™, Avita's chronic wounds device that is used to treat long standing wounds such as Venous Leg Ulcers and Diabetic Foot Ulcers
Part 3 concludes with the RESTORE session which looked at the use of ReNovaCell™, Avita's device which covers aesthetic applications including vitiligo and scarring

During the Symposium, Regenerative Medicine interviewed leading clinicians about their experience pioneering Avita Medical's autologous skin healing technology based on its RES™ -- Regenerative Epithelial Suspension -- technology that uses just a small sample of the patient's skin. The experts had all presented strong clinical results in their various areas of expertise, and agreed that a call for action is now needed to move Avita's medical devices into mainstream medical practice, to improve lives of patients, whilst saving healthcare costs.
"This versatile technology could be used in a number of ways in the same patient without an incremental increase in cost, since length of stay can be reduced so dramatically," said Dr James H. Holmes IV, Wake Forest University School of Medicine. "That can have a huge impact on the healthcare system and society as a whole, since the patient is able to return to a functional state more quickly: whether that's going back to work, or driving a car." His views were shared by Mr Paul Hayes, Vascular Surgeon at Addenbrooke's Hospital, who explained that VLUs consume 10-20% of vascular surgery clinic time, while great resources were also being spent on treating Britain's some 100,000 DFU patients1. Mr Hayes said it was much cheaper to treat patients as an out-patient, which was one of the attractions to ReGenerCell™. "If acute wounds are referred into secondary care earlier, we could actually stop them from being so difficult to treat," Mr Hayes commented. "With the exception of diabetic foot ulcers, chronic wounds have not become headline-grabbing conditions. So we need to have a group of interested individuals who can be dedicated to the cause." Dr Nik Georgopoulos, Senior Lecturer, Department of Biological Sciences at the University of Huddersfield, supported Mr Hayes call for action, saying, "By supporting the way the device operates with biological evidence we are able to give more confidence to the clinicians who use it on its efficacy. The economic burden of chronic wounds is not in the range of the millions (of pounds), it's in the range of billions." Adam Kelliher, CEO of Avita Medical, concluded: "Regenerative medicine and using the body's own healing responses is becoming more widespread in medical practice. The body of data supporting the efficacy of our devices is growing every day. Whilst mainstream adoption of new technologies rightly takes time, the clinicians pioneering our technology agree that barriers to widespread uptake need to be overcome. The use of Avita's technology positively impacts patients with quicker and more significant wound healing, less inconvenience and much less pain." Indicators have shown Avita's technology also saves money for healthcare services when replacing or combined with traditional methods, the Company says. It will be gathering important pharmaco-economic data during its ongoing clinical studies, to support adoption of its products. With data collected from over 6,000 procedures worldwide, Avita's patented technology is CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. 1 https://www.diabetes.org.uk/FactsandStats ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected] / [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...
Avita Medical Awarded US$7.96m in BARDA Extension Deal

NORTHRIDGE, CA and PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 26, 2016) - Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY)

Additional non-dilutive funds to accelerate US market approval and product launch
Support aims to increase familiarity/acceptance in US Burn Centers, demonstrate economic benefits and increase acceptance of ReCell® in US Burn Centers
Funds will be deployed to support recruitment of additional US operational staff

A US Federal authority charged with supporting development of medical countermeasures for possible mass casualty events has agreed to fund Avita Medical a further $US7.96 million to support the regenerative medicine company in its plans for US market approval and product launch of ReCell®, the Company said today. Avita Medical Limited, (ASX: AVH) (OTCQX: AVMXY) which makes Autologous Cell Harvesting Devices for treatment of burns, chronic wounds and certain aesthetic conditions, said the award supplements the contract executed last September with the Biomedical Advanced Research and Development Authority (BARDA), worth up to $US53.9m. The initial contract with BARDA, an authority under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services, includes procurement and various elements of support for late-stage development of ReCell®. The new contract addendum, worth up to $US7.96 million (AUD $11m), commences immediately, giving further operational support to facilitate the overarching objective of BARDA for preparedness via securing effective treatment of burn injuries secondary to detonation of a nuclear device. The additional funds will bolster ongoing work toward the Company's filing of a PMA application, along with funding new initiatives toward gaining familiarity and acceptance of ReCell® within US Burn Centers, including health economic modelling of the benefits associated with ReCell® for burns treatment and continuing engagement with US Burn Centers for use of ReCell® under the Company's open Investigational Device Exemptions (IDEs) for treatment of a range of burn injuries including the particularly extensive burns associated with Compassionate Use. Towards this, Avita will utilize these funds towards recruitment of new personnel at the Company's office in Northridge, California. The new staff will be focused on such operational areas as regulatory, supply chain, quality systems, clinical support and reimbursement. "This welcome infusion of significant non-dilutive capital to fund our activities in the US, which we would otherwise have had to fund ourselves, greatly supports Avita Medical on its commercial journey," said Avita CEO Adam Kelliher. "We are particularly excited about the health economics support, which we hope will enable us to show how innovative approaches such as ours can both help burn victims and save money as these are the key drivers to support our reimbursement efforts." BARDA's initial contract funds the completion of Avita's FDA approval trial, for which all treatments have now been completed, and the cohort is currently being observed over a 52-week safety period. As well as an initial procurement of some 5,000 devices, the contract also funds an education programme, so that burns surgeons across the US will be trained as well as supplied with the medical devices, should there be a mass casualty event involving numerous burn injuries. The procurement order could be placed prior to FDA approval based on the possibility for deployment of ReCell® devices under an Emergency Use Authorisation. The Company said it is in close communication with BARDA on the progress of its FDA approval pathway, which is scheduled to complete in calendar Q3 2017.  ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin. ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit www.avitamedical.com.


FOR FURTHER INFORMATION


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: 44 (0) 1763 269 772

[email protected]


Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: 1 (818) 356-9400

[email protected]


Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone 61(0) 8 9474 7738

[email protected]


UK/EU

Instinctif Partners

Gemma Howe/Sue Charles

Phone 44 (0)20 7866 7860

[email protected]


USA

The Ruth Group

David Burke

Investor Relations

Kirsten Thomas

Public Relations

Phone: 1 (646) 536-7009 / 1 (508) 280-6592

[email protected] / [email protected]


Australia

Monsoon Communications

Dean Felton

Investor Relations / PR

Phone: 61 3 9620 3333

Mobile: 61 (0) 411 698 499

[email protected]





Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.15
AVMXY's PB Ratio is ranked lower than
77% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. AVMXY: 6.15 )
Ranked among companies with meaningful PB Ratio only.
AVMXY' s PB Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.79 Max: 15
Current: 6.15
0.21
15
PS Ratio 40.00
AVMXY's PS Ratio is ranked lower than
94% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. AVMXY: 40.00 )
Ranked among companies with meaningful PS Ratio only.
AVMXY' s PS Ratio Range Over the Past 10 Years
Min: 1.43  Med: 9.29 Max: 70
Current: 40
1.43
70
EV-to-EBIT -4.18
AVMXY's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 24.65 vs. AVMXY: -4.18 )
Ranked among companies with meaningful EV-to-EBIT only.
AVMXY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.8  Med: -2.4 Max: 1.2
Current: -4.18
-8.8
1.2
EV-to-EBITDA -4.18
AVMXY's EV-to-EBITDA is ranked lower than
99.99% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 18.57 vs. AVMXY: -4.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVMXY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.3  Med: -2.7 Max: 2
Current: -4.18
-14.3
2
Current Ratio 4.86
AVMXY's Current Ratio is ranked higher than
78% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. AVMXY: 4.86 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.9 Max: 126.2
Current: 4.86
0.3
126.2
Quick Ratio 4.08
AVMXY's Quick Ratio is ranked higher than
77% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. AVMXY: 4.08 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.59 Max: 126.2
Current: 4.08
0.3
126.2
Days Inventory 892.52
AVMXY's Days Inventory is ranked lower than
100% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. AVMXY: 892.52 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s Days Inventory Range Over the Past 10 Years
Min: 157  Med: 358.08 Max: 892.52
Current: 892.52
157
892.52
Days Sales Outstanding 736.19
AVMXY's Days Sales Outstanding is ranked lower than
100% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 68.69 vs. AVMXY: 736.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.69  Med: 179.48 Max: 736.19
Current: 736.19
98.69
736.19
Days Payable 1.00
AVMXY's Days Payable is ranked lower than
99% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. AVMXY: 1.00 )
Ranked among companies with meaningful Days Payable only.
AVMXY' s Days Payable Range Over the Past 10 Years
Min: 112.97  Med: 328.22 Max: 1400.07
Current: 1
112.97
1400.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.40
AVMXY's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 230 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. AVMXY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVMXY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -36.6 Max: 0
Current: -17.4
-93.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.00
AVMXY's Price-to-Net-Cash is ranked higher than
65% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 15.75 vs. AVMXY: 8.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVMXY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.08  Med: 4.07 Max: 25.2
Current: 8
1.08
25.2
Price-to-Net-Current-Asset-Value 8.00
AVMXY's Price-to-Net-Current-Asset-Value is ranked lower than
56% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.69 vs. AVMXY: 8.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVMXY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 3.89 Max: 19.38
Current: 8
1.07
19.38
Price-to-Tangible-Book 6.15
AVMXY's Price-to-Tangible-Book is ranked lower than
64% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.84 vs. AVMXY: 6.15 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVMXY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.95  Med: 3.5 Max: 18.33
Current: 6.15
0.95
18.33
Price-to-Median-PS-Value 4.00
AVMXY's Price-to-Median-PS-Value is ranked lower than
97% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. AVMXY: 4.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVMXY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.43 Max: 13.26
Current: 4
0.42
13.26
Earnings Yield (Greenblatt) % -23.92
AVMXY's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. AVMXY: -23.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVMXY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17832.2  Med: -30.95 Max: 11345.6
Current: -23.92
-17832.2
11345.6

More Statistics

Revenue (TTM) (Mil) $0.74
EPS (TTM) $ -0.23
Beta-0.04
Short Percentage of Float0.00%
52-Week Range $1.22 - 2.24
Shares Outstanding (Mil)33.66 (ADR)
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell® in a Mass Ca May 10 2017 
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux Oct 19 2016 
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell(R) in Life-Threaten Oct 18 2016 
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida Oct 13 2016 
FDA Approves Continued Access to ReCell(R) in US Burns Trial Oct 04 2016 
Avita Medical Signs Exclusive Distributor Deal in Iran Sep 29 2016 
Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course Sep 22 2016 
Avita Medical Appoints a Leading Health Economics Group Jun 28 2016 
Regenerative Medicine Publishes Key Findings From Avita Medical's 2016 Skin Regeneration Symposium Jun 27 2016 
Avita Medical Awarded US$7.96m in BARDA Extension Deal Jun 26 2016 

More From Other Websites
New Randomized Trial Shows ReCell® Heals Donor Sites Faster Jun 19 2017
Dr Michael S. Perry Appointed Avita Medical CEO Jun 01 2017
Avita Medical’s Board Show Confidence in Company by Taking Payment in Shares May 22 2017
Avita Medical Announces Positive Results from Pivotal Trial May 17 2017
Avita Medical Initiates Legal Proceedings to Cancel Renovacare Patent May 10 2017
Initial Pre-Emergency Use Authorization Submission Made to U.S. FDA for Use of ReCell® in a Mass... May 10 2017
Avita Medical CEO Shareholder Letter and Quarterly Report Apr 27 2017
U.S. FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell® in... Apr 06 2017
Avita Medical to Present at Needham Healthcare Conference Mar 23 2017
Avita Announces Receipt of $975K R&D Tax Incentive Mar 15 2017
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial Mar 06 2017
Avita Medical Named to 2017 OTCQX Best 50 Feb 28 2017
Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017... Jan 24 2017
Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits... Nov 28 2016
Innovative Regenerative Approach to Healing Diabetic Foot Ulcers Now Being Trialed at Two Additional... Nov 08 2016
Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux Oct 19 2016
Avita Medical to Present at the 2016 Dawson James Securities Growth Stock Conference in Florida Oct 13 2016
Avita Medical Signs Exclusive Distributor Deal in Iran Sep 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}